Survivin DC cell therapy (Qichensheng Biotechnology)

靶向Survivin DC细胞（启辰生生物）

Report date: 2026/04/20 20:01:59

Base Information

Drug NameSurvivin DC cell therapy (Qichensheng Biotechnology)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy
Mechanisms of ActionBaculoviral IAP repeat-containing protein 5 modulators
TargetsBaculoviral IAP repeat-containing protein 5
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesQichensheng Biotechnology (Zhuhai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesQichensheng Biotechnology (Zhuhai) Co LtdBeijing Tricision Biotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A